In this issue:
Cardiovascular disease risk with biologics
Ustekinumab biosimilar in moderate-to-severe plaque psoriasis
Use and cost of first-line biologics to treat plaque psoriasis
Bimekizumab after 3 years in moderate-to-severe plaque psoriasis
Risk of herpes zoster and postherpetic neuralgia with biologics
Ustekinumab biosimilar ABP 654 in moderate-to-severe plaque psoriasis
Age and biologic survival in moderate-to-severe psoriasis
Long-term cardiovascular safety of ustekinumab
Biologics and risk of new-onset and recurrent MACE
Risk of MACE and VTE between TNF, IL-17, IL-12/23 and IL-23 inhibitors
Please login below to download this issue (PDF)